|
Pronunciation |
|
(hye
droe floo meth EYE a
zide) |

|
|
U.S. Brand
Names |
|
Diucardin®;
Saluron® |

|
|
Generic
Available |
|
Yes |

|
|
Pharmacological Index |
|
Diuretic, Thiazide |

|
|
Use |
|
Management of mild to moderate hypertension; treatment of edema in congestive
heart failure and nephrotic syndrome |

|
|
Pregnancy Risk
Factor |
|
D |

|
|
Contraindications |
|
Hypersensitivity to hydroflumethiazide or any component, thiazides, or
sulfonamide-derived drugs; anuria; renal decompensation |

|
|
Warnings/Precautions |
|
Avoid in severe renal disease (ineffective). Electrolyte disturbances
(hypokalemia, hypochloremic alkalosis, hyponatremia) can occur. Use with caution
in severe hepatic dysfunction; hepatic encephalopathy can be caused by
electrolyte disturbances. Gout can be precipitate in certain patients with a
history of gout, a familial predisposition to gout, or chronic renal failure.
Cautious use in diabetics; may see a change in glucose control. Hypersensitivity
reactions can occur. Can cause SLE exacerbation or activation. Use with caution
in patients with moderate or high cholesterol concentrations. Photosensitization
may occur. Correct hypokalemia before initiating therapy. |

|
|
Adverse
Reactions |
|
1% to 10%: Endocrine & metabolic: Hypokalemia
<1% (Limited to important or life-threatening symptoms): Hypotension,
drowsiness, photosensitivity, rash, fluid and electrolyte imbalances
(hypocalcemia, hypomagnesemia, hyponatremia), hyperglycemia, anorexia, polyuria,
aplastic anemia, hemolytic anemia, leukopenia, agranulocytosis,
thrombocytopenia, rarely blood dyscrasias, hepatitis, paresthesia, prerenal
azotemia, uremia |

|
|
Overdosage/Toxicology |
|
Symptoms of overdose include hypermotility, diuresis, lethargy
Following GI decontamination, therapy is supportive with I.V. fluids,
electrolytes, and I.V. pressors if needed |

|
|
Drug
Interactions |
|
Angiotensin-converting enzyme inhibitors: Increased hypotension if
aggressively diuresed with a thiazide diuretic.
Beta-blockers increase hyperglycemic effects in Type 2 diabetes mellitus.
Cyclosporine and thiazides can increase the risk of gout or renal toxicity;
avoid concurrent use.
Digoxin toxicity can be exacerbated if a thiazide induces hypokalemia or
hypomagnesemia.
Lithium toxicity can occur by reducing renal excretion of lithium; monitor
lithium concentration and adjust as needed.
Neuromuscular blocking agents can prolong blockade; monitor serum potassium
and neuromuscular status.
NSAIDs can decrease the efficacy of thiazides reducing the diuretic and
antihypertensive effects. |

|
|
Mechanism of
Action |
|
The diuretic mechanism of action is primarily inhibition of sodium, chloride,
and water reabsorption in the renal distal tubules, thereby producing diuresis
with a resultant reduction in plasma volume |

|
|
Pharmacodynamics/Kinetics |
|
Onset of diuretic effect: Within ~2 hours
Peak effect: Within ~4 hours
Duration of action: 12-24 hours |

|
|
Usual Dosage |
|
Oral:
Adults:
Edema:
Initial: 50 mg 1-2 times/day
Maintenance: 25-200 mg/day (use divided doses when >100 mg/day)
Hypertension:
Initial: 50 mg twice daily
Maintenance: 50-100 mg/day; maximum: 200 mg/day |

|
|
Monitoring
Parameters |
|
Assess weight, I & O reports daily to determine fluid loss; blood
pressure, serum electrolytes, BUN, creatinine |

|
|
Test
Interactions |
|
ammonia (B),
amylase (S),
calcium (S),
chloride (S),
glucose,
uric acid (S);
chloride (S),
magnesium,
potassium (S),
sodium
(S)
|

|
|
Cardiovascular
Considerations |
|
Thiazide diuretics are effective first-line therapeutic agents in the
management of hypertension and have proven to be of benefit in terms of
cardiovascular outcome. They may act synergistically to lower blood pressure
when combined with an ACE inhibitor or beta-blocker. The initial concern about
thiazide diuretic-induced hypokalemia, glucose intolerance, and lipid profiles
does not appear to be of substantial clinical consequence in the treatment of
hypertension. The benefits of this class of agents in the treatment of
hypertension is established and compares well with other first-line therapeutic
agents. |

|
|
Mental Health: Effects
on Mental Status |
|
May cause drowsiness |

|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
May rarely cause agranulocytosis; use caution with clozapine and
carbamazepine; may decrease lithium clearance resulting in an increase in serum
lithium levels and potential lithium toxicity; monitor serum lithium
levels |

|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |

|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |

|
|
Patient
Information |
|
May be taken with food or milk; take early in day to avoid nocturia; take the
last dose of multiple doses no later than 6 PM unless instructed otherwise. A
few people who take this medication become more sensitive to sunlight and may
experience skin rash, redness, itching or severe sunburn, especially if sun
block SPF greater than or equal to 15 is not used on exposed skin
areas. |

|
|
Nursing
Implications |
|
Take blood pressure with patient lying down and standing |

|
|
Dosage Forms |
|
Tablet: 50 mg |

|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|